What Preceptis Medical does

Preceptis Medical is a privately held Minnesota-based medical device company that develops and commercializes the Hummingbird Tympanostomy Tube System (TTS), an FDA-cleared single-pass device that enables ENT surgeons to perform pediatric ear tube placement in the office without general anesthesia. Founded in 2011, the company targets the roughly 1 million pediatric ear tube procedures performed annually in the United States, a market contributing approximately $3 billion in annual healthcare costs. The device replaces the conventional OR-based surgical workflow (which can exceed $5,000 per case) with a topical-anesthetic, in-office procedure completed in under five minutes, addressing parental concerns about anesthesia, surgical scheduling constraints, and healthcare access inequities.

The Hummingbird TTS combines myringotomy incision and tube delivery into a single mechanical pass using a cutting sheath and slider, replacing the multi-step, multi-tool traditional procedure. The technology is protected by eight US patents and holds FDA 510(k) clearances (K200952 and K221254), initially approved in 2020 for children 6-24 months and expanded in August 2022 to all children 6 months and older. Clinical evidence supports a 98-99% in-office success rate, 100% tolerability with topical anesthetic, a median bilateral procedure time under five minutes, and a 97% parent recommendation rate, with no reported serious adverse events in clinical studies.

Preceptis generates revenue through direct unit sales of the Hummingbird device at under $1,000 per unit to ENT practices and hospital systems, a price point that delivers up to 65-68% cost savings versus traditional OR-based procedures. The company sells primarily via direct field sales to mid-market ENT groups and enterprise hospital systems, with channel expansion underway through a major Medicaid payer pilot (December 2023) and an AcuityMD commercial partnership (October 2025). A new CMS HCPCS add-on code G0561, effective January 1, 2025, now provides standardized reimbursement for in-office pediatric tympanostomy procedures performed with a tube delivery device. The company has raised $26 million in total investor capital, primarily from affluent individuals and a Chinese medical concern (with $1 million from Children's Minnesota), and has deliberately avoided traditional venture capital financing. The company is headquartered in Golden Valley, Minnesota, with 11-50 employees and operates exclusively in the United States.

Name

Preceptis Medical

Legal name

Preceptis Medical, Inc.

Website

https://hummingbirdeartubes.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

Preceptis Medical develops and sells the FDA-cleared Hummingbird TTS, a single-pass device that enables in-office pediatric ear tube placement without general anesthesia, marketed directly to ENT practices and hospital systems across the United States.

Ownership category

akta.pro rank

Product category

Pediatric Otology Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools) (HLAHADAN)

Keywords

• Pediatric ear tube devices
• Tympanostomy tube systems
• In-office ENT procedures
• Minimally invasive otology
• Pediatric surgical instruments

Headquarters

HQ city

Maple Grove

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations

Revenue model

1. Hummingbird TTS Device Sales: Preceptis Medical generates revenue through the sale of its Hummingbird Tympanostomy Tube System medical devices to ENT practices and hospital systems. The device costs less than $1,000 per unit. Revenue is derived from direct sales to healthcare providers who perform in-office ear tube procedures.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Core offering

Preceptis Medical designs, develops, and manufactures the FDA-cleared Hummingbird Tympanostomy Tube System (TTS), a single-pass medical device that allows ENT surgeons to perform pediatric ear tube placement in-office using only topical anesthesia, eliminating the need for general anesthesia and operating room procedures. The device combines myringotomy incision creation and tympanostomy tube placement into a single motion through the eardrum.

Product overview

Preceptis Medical offers a single unified product: the Hummingbird® Tympanostomy Tube System (TTS), an FDA-cleared medical device for pediatric ear tube placement. The Hummingbird TTS is a single-pass device that enables ENT surgeons to perform ear tube insertion in their office using only topical anesthesia, eliminating the need for general anesthesia and operating room procedures. The product has evolved from its original 2020 clearance (for children 6-24 months) to an expanded 2022 labeling covering all children 6 months and older, and launched a next-generation version in 2021 with enhanced ergonomic design.

Differentiator

Problem solved

Functional benefit

Brands

• Hummingbird TTS: Hummingbird Tympanostomy Tube System - an FDA-cleared device enabling in-office pediatric ear tube placement without general anesthesia
• Hummingbird Procedure
• One-Pass Technology

Products and services

• Hummingbird Tympanostomy Tube System (TTS)
• Next-Generation Hummingbird Tympanostomy Tube System

Quantifiable outcome

• Up to 65-68% cost reduction compared to traditional OR-based ear tube surgery
• +5 more outcomes

Named customers7 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• AcuityMDcoreGTM or Marketing Partner · 21 October 2025Preceptis Medical selected AcuityMD to support the expansion of its in-office pediatric ear tube device. This partnership aims to enhance the device's deployment and commercial expansion.
• Major Medicaid Payer (Pilot Program)coreStrategic or Co-development Partner · 6 December 2023Collaboration with one of the largest Medicaid payers in the United States for a pilot program expanding access to Hummingbird in-office ear tube procedures for Medicaid populations. This partnership addresses healthcare access inequities and OR scheduling constraints.
• Mayo CliniccoreStrategic or Co-development PartnerMayo Clinic was a lead clinical trial site for the Hummingbird device. Dr. Shelagh Cofer served as lead investigator and senior author of the peer-reviewed study published in Laryngoscope Investigative Otolaryngology.
• HealthPartnersminorStrategic or Co-development PartnerHealthPartners was among the early ordering customers for the Hummingbird device and participated in the commercial pilot program.
• St. Cloud Ear, Nose & ThroatcoreStrategic or Co-development PartnerDr. Ted Truitt of St. Cloud ENT was the primary author and one of the lead investigators for the clinical trial. St. Cloud ENT was among the first practices to order the Hummingbird device.
• Phoenix Children's HospitalminorStrategic or Co-development PartnerPhoenix Children's Hospital was one of the first hospitals in the nation to use the Hummingbird device. Dr. Nathan Page worked with Mayo Clinic to bring the device to Arizona.
• Children's Hospital ColoradominorStrategic or Co-development PartnerChildren's Hospital Colorado began offering the Hummingbird procedure as one of the first patients to receive ear tubes with the device at the hospital.
• Cedars-SinaiminorStrategic or Co-development PartnerCedars-Sinai was one of the initial eight institutions across the country involved in clinical trials of the Hummingbird device.
• PENTA (Pediatric Ear, Nose & Throat of Atlanta)minorStrategic or Co-development PartnerDr. Paula Harmon of PENTA participated in the Medicaid insurer pilot program and was voted a Top ENT Doctor in a national listing in 2022.

Scale indicators7 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Stryker: Large diversified medical device and surgical instruments manufacturer. Comparable as a broad surgical/medical device incumbent with overlapping sales channels into ENT and pediatric OR settings.
• Olympus Corporation: Manufacturer of ENT endoscopes and surgical instruments, with deep presence in ENT offices and ORs. Adjacent competitor in the ENT surgical device category.
• Medtronic: Medtronic manufactures traditional tympanostomy/ear tubes and broader ENT surgical products. Incumbent with existing hospital relationships; would likely be a partner, acquirer, or direct competitor in pediatric ENT.
• Johnson & Johnson (Acclarent): Acclarent (J&J) is a leader in ENT intervention devices (e.g., balloon sinuplasty). Broad incumbent in ENT with the commercial scale and ENT relationships to either develop or distribute competing in-office pediatric products.
• KARL STORZ: Global manufacturer of endoscopes and ENT surgical instruments used in ear tube procedures. Broad incumbent in ENT visualization and instrumentation.

Direct peers

• Smith+Nephew (Tusker Medical): Smith+Nephew acquired Tusker Medical, which was developing a competing in-office pediatric tympanostomy tube delivery system (Tula). Most directly comparable peer as a same-category, same-indication, in-office ear tube competitor.
• Cook Medical: Cook Medical manufactures tympanostomy (ear) tubes and other ENT products. Directly comparable as an established ear tube manufacturer supplying the same clinical workflow.
• Grace Medical: Specialty manufacturer of ENT surgical products including tympanostomy tubes and middle-ear prostheses. Directly comparable as a focused ear-tube and middle-ear surgical product competitor.

Emerging players

• Intersect ENT: ENT-focused device company (acquired by Medtronic) specializing in office-based sinuplasty products. Comparable as a focused ENT device company that drove the shift from OR to office procedures in a parallel category.

Others

• AcuityMD: Medical device commercial-intelligence platform announced as Preceptis' GTM partner in October 2025. Comparable as a commercial-enablement partner serving the med-device go-to-market motion.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/preceptismed
• LinkedInlinkedin.com/company/preceptis-medical-inc-

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds10 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Preceptis Medical